Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today

NEW YORK (TheStreet) -- Tekmira Pharmaceuticals (TKMR) shares are up 11.5% to $15.90 on Monday in response to the FDA's announcement that it "stands ready" to work with companies fighting an outbreak of Ebola that has killed over 700 people in six months.

The stock is trading on heavy volume with 6 million shares changing hands in early trading, well ahead of its three month daily average of 390,980 shares.

This announcement raises hopes for Tekmira's TKM-Ebola Phase 1 Ebola treatment, which the agency placed a clinical hold on last month.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The hold means that the company cannot continue the same clinical trial that the FDA stopped, but the company could propose a new trial.

A senior official at the FDA told Reuters that "the agency would consider proposals for providing treatments under special emergency new drug applications" if the proposed treatment landed on the right side of the agency's cost-benefit analysis.

Analysts at TheStreet believe that investors buying Tekmira stocks in anticipation of benefiting from the potential increased demand may be betting on the wrong horse.

TKMR ChartTKMR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Tekmira Pharmaceuticals (TKMR) Weak On High Volume

Tekmira Pharmaceuticals (TKMR): Today's Weak On High Volume Stock

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst